/DISCLAIMER · RESEARCH_COMPOUND

This page is reference information only. Most compounds described here are research chemicals, not FDA-approved medications. MyTRT does not sell, recommend, or endorse the use of these substances. Always consult a qualified physician.

/SEMA_GLP_1
Peptide

Sema GLP-1

GLP-1 Receptor Agonist

/HALF_LIFE
About 7 days
/DELIVERY
Subcutaneous injection

/WHAT_IT_IS

Semaglutide is a GLP-1 receptor agonist that mimics the effects of glucagon-like peptide-1, helping regulate blood sugar and suppress appetite.

/USAGE

Commonly studied for weight loss, appetite control, and blood glucose regulation in individuals with metabolic conditions such as Type 2 diabetes and obesity.

/MECHANISM_OF_ACTION

Activates GLP-1 receptors to enhance insulin secretion, slow gastric emptying, suppress appetite, and reduce glucagon secretion.

Reported Benefits

  • +Appetite suppression
  • +Weight loss
  • +Improved blood sugar control
  • +Reduced risk of cardiovascular events

Reported Side Effects

  • Nausea
  • Constipation
  • Headache
  • Loss of appetite

/STACKED_WITH

CagrilintideTesofensineBPC-157

/RESEARCH_NOTES

Semaglutide has become a leading GLP-1 analog in obesity and diabetes research, with strong clinical data supporting its effectiveness.

/REFERENCE

https://pubmed.ncbi.nlm.nih.gov/39476339/

/RELATED

/TRACK_THIS

Browse all 89 in the app.

MyTRT's in-app library has the same 89 peptide entries plus dosing notes, stack builders, and the ability to log them alongside your TRT protocol.

Last reviewed: 2026-06-04 · Reference only. Not medical advice. Consult a qualified physician.